Clinical trials: Control Subjects
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00039026
- Testing
- AC2993
- Where
- 126 sites in United States
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).
- Trial name
- VOCAL (NCT05288855)
- Testing
- Voclosporin
- Where
- 6 sites in United States, Colombia and 3 more
- Volunteers
- 9 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Cystic Fibrosis
A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
The primary purpose of study is to evaluate the treatment effect of tezacaftor in combination with ivacaftor (TEZ/IVA) on chest imaging endpoints using low-dose computed tomography (LDCT) at Week 72, and to evaluate the safety of…
- Trial name
- NCT02730208
- Testing
- Tezacaftor/Ivacaftor, Ivacaftor
- Where
- 9 sites in Australia
- Volunteers
- 41 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Molluscum Contagiosum
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum (VBP-245-MCV).
- Trial name
- NCT03077750
- Testing
- VBP-245 Topical Gel, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Veloce BioPharma LLC
Dermatitis, Dermatitis, Atopic
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- NCT03627767
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 235 sites in United States, Argentina and 19 more
- Volunteers
- 1,235 people
- Sponsor
- Pfizer
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris
The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory…
- Trial name
- NCT02571998
- Testing
- Omiganan (CLS001) Topical Gel, Vehicle Topical Gel
- Where
- 29 sites in United States
- Volunteers
- 320 people
- Sponsor
- Maruho Co., Ltd.
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CardiganI (NCT03836287)
- Testing
- Sofpironium Bromide Gel, 15%, Vehicle
- Where
- 39 sites in United States
- Volunteers
- 350 people
- Sponsor
- Botanix Pharmaceuticals
Grade 2 Glioma, Residual Glioma
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2…
- Conditions
- Grade 2 Glioma, Residual Glioma, Recurrent Glioma
- Trial name
- NCT04164901
- Testing
- Vorasidenib
- Where
- 84 sites in United States, Canada and 9 more
- Volunteers
- 331 people
- Sponsor
- Institut de Recherches Internationales Servier
Epilepsy With Partial-onset Seizures
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications.
- Trial name
- NCT02477839
- Testing
- Lacosamide
- Where
- 88 sites in United States, Argentina and 24 more
- Volunteers
- 255 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Crohn's Disease
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.
- Trial name
- NCT00074542
- Testing
- Epanova™ (Omega-3 Free Fatty Acids)
- Where
- 31 sites in United States, Canada
- Volunteers
- 364 people
- Sponsor
- Tillotts Pharma AG
Acute Spinal Cord Injury
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, SUN13837 Injection, when compared with the placebo (inactive substance) in participants with acute spinal cord…
- Trial name
- NCT01502631
- Testing
- SUN13837 injection
- Where
- 67 sites in United States, Canada and 5 more
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Lower Respiratory Tract Infection, Parainfluenza
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
- Conditions
- Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
- Trial name
- NCT03808922
- Testing
- DAS181, DAS181 COVID-19, DAS181 OL
- Where
- 28 sites in United States, Australia and 3 more
- Volunteers
- 274 people
- Sponsor
- Ansun Biopharma, Inc.
Type 2 Diabetes Mellitus
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet…
- Trial name
- NCT00308139
- Testing
- exenatide, long acting release, exenatide
- Where
- 25 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- AstraZeneca
Asthma
Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects
This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.
- Trial name
- NCT01453296
- Testing
- GW642444
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study.
- Trial name
- ENVISION (NCT05881408)
- Testing
- delandistrogene moxeparvovec
- Where
- 46 sites in United States, Australia and 12 more
- Volunteers
- 148 people
- Sponsor
- Sarepta Therapeutics, Inc.
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
- Trial name
- NCT04873869
- Testing
- NBI-921352
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences
Epilepsy
Pediatric Epilepsy Trial in Subjects 1-24 Months
This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures.
- Trial name
- NCT00043875
- Testing
- lamotrigine
- Where
- 65 sites in United States, Australia and 12 more
- Volunteers
- 177 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Tonic-Clonic
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
The purpose of this study is to evaluate the effectiveness and safety of an investigational new drug for supplemental therapy in subjects with primary generalized tonic-clonic (PGTC) seizures.
- Trial name
- NCT00043901
- Testing
- lamotrigine
- Where
- 87 sites in United States, Argentina and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Hematologic Malignancies, Acute Myeloid Leukemia
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
The purpose of this study is to determine the efficacy and safety of transplanting StemEx® in patients with certain hematological malignancies.
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia
- Trial name
- ExCell (NCT00469729)
- Testing
- StemEx®
- Where
- 30 sites in United States, Hungary and 3 more
- Volunteers
- 101 people
- Sponsor
- Gamida Cell -Teva Joint Venture Ltd.
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
- Trial name
- NCT01017146
- Testing
- Tazarotene foam, Vehicle Foam
- Where
- 22 sites in United States, Canada
- Volunteers
- 744 people
- Sponsor
- Stiefel, a GSK Company